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Many treatments used for childhood cancer can produce
reproductive toxicity. Well-known examples include the
teratogenicity of both radiation therapy (Otake and
Schull 1984; Brent et al. 1993) and methotrexate treat-
ment (Milunsky et al. 1968; Warkany 1978) and the
induction of oligospermia by treatment with cyclophos-
phamide (Watson et al. 1985; Meistrich et al. 1992).
Many of these treatments can also cause heritable ge-
netic changes in mice and other laboratory animals (San-
karanarayanan 1991; Witt and Bishop 1996). Although
human and other mammalian germ cells differ in their
susceptibility to induced mutations, the processes of ga-
metogenesis and mutagenesis in humans and in labo-
ratory mammals are fundamentally similar (Favor 1993;
Shelby 1994). It therefore seems likely that treatment of
affected children with mutagenic agents could produce
germ-cell mutations and consequent genetic disease in
the next generation.
The question of greatest clinical importance, however,
is not whether anticancer treatments can actually be
shown to cause mutations in human germ cells but
whether these therapies increase the frequency of genetic
disease in the children of treated individuals. Clearly,
potentially mutagenic treatments do not always cause
germ-cell mutations that are transmitted to the next gen-
eration, and mutations that are transmitted do not al-
ways produce genetic disease in the offspring
(Sankaranarayanan 1994; Shelby 1994). The paper by
Byrne et al. (1998) in this issue of the Journal helps to
answer this question.
Byrne et al. studied the frequency of congenital anom-
alies and genetic diseases among 2,198 children of in-
dividuals who survived a brain tumor or malignancy
during childhood or adolescence. Their paper is re-
markable for several reasons. The first is the large size
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of the study cohort, which provides sufficient statistical
power to exclude a doubling of the overall rate of con-
genital anomalies. Previous investigations have involved
far fewer children (Klein 1996; Dodds et al. 1993; Ken-
ney et al. 1996; Green et al. 1997).
Second, Byrne et al. have carefully divided the con-
genital anomalies observed into those that are likely to
have resulted from a germ-cell mutation and those that
are not. Although this reduces the number of abnormal
outcomes in each group, restricting the analysis to those
most likely to have abnormalities resulting from new
mutations may nevertheless increase the statistical power
of the study (Friedman 1992). Congenital anomalies re-
sulting from germ-cell mutations are uncommon com-
pared with congenital anomalies resulting from other
causes, and an effect restricted to the former may often
be lost in the “background noise” of the latter if all
congenital anomalies are considered together. Byrne et
al. also distinguish between children whose parent sur-
vived cancer after receiving a potentially mutagenic
treatment and children whose parent survived cancer
without such treatment. It is only in the former group
that a mutagenic effect on the germ cells would be
expected.
This division of the data into subsets based on bio-
logical plausibility is most fully exploited by Byrne et al.
in a nested case-control study within the cohort of chil-
dren of cancer survivors. Neither this case-control study
nor the full cohort study of children of cancer survivors
provides any indication that cancer chemotherapy or
radiotherapy measurably increases the risk of congenital
anomalies in children who are subsequently conceived.
This good news is tempered by the fact that the data
are partially out of date. Collection of data concluded
in 1983, and cancer was diagnosed in the parents of
members of the study cohort during 1945–1975. The
inclusion criteria stipulate that a cancer survivor must
have reached the age of 21 years between 1946 and
1980. Only the youngest members of this group are
likely still to be having children.
Both therapy for childhood malignancy and the out-
come of such treatment have come a long way since
1975. For example, very few of the survivors in this
study had acute lymphoblastic leukemia, a disease that
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would account for a large proportion in any contem-
porary series of childhood-cancer survivors (Hammond
1997).
The only mutagenic drugs considered in the study
were alkylating agents. These drugs are still widely used,
but many additional cancer chemotherapeutic agents
have been introduced in the intervening years (e.g., see
Haskell 1980, 1995). Most of these newer drugs have
been shown to be mutagenic in at least some test systems
(Harrison 1996), and, in most instances, themutagenesis
occurs by a mechanism that is different from that of the
alkylating agents (Perry 1996). As Byrne et al. point out,
studies of the children of more-recent cohorts of child-
hood-cancer survivors will be necessary to determine the
reproductive effects of contemporary cancer treatments.
Exposure to sufficiently high doses of ionizing radi-
ation or mutagenic drugs must be capable of producing
transmissible genetic alterations in the germ cells of hu-
mans. From a practical point of view, however, the risk
of congenital anomalies among the children of cancer
survivors does not appear to be measurably different
from the risk of congenital anomalies among the general
population. This is reassuring information for child-
hood-cancer survivors who would like to have children
of their own.
References
Brent R, Meistrich M, Paul M (1993) Ionizing and nonionizing
radiations. In: Paul M (ed) Occupational and environmental
reproductive hazards: a guide for clinicians.Williams&Wil-
kins, Baltimore, pp 165–189
Byrne J, Rasmussen SA, Stelnhorn SC, Connelly RR, Myers
MH, Lynch CF, Flannery J, et al (1998) Genetic disease in
offspring of long-term survivors of childhood and adolescent
cancer. Am J Hum Genet 62:000–000 (in this issue)
Dodds L, Marrett LD, Tomkins DJ, Green B, Sherman G
(1993) Case-control study of congenital anomalies in chil-
dren of cancer patients. Br Med J 307:164–168
Favor J (1993) Genetic effects from exposure to hazardous
agents. Environ Health Perspect 101 Suppl 3:263–267
Friedman JM (1992) The use of dysmorphology in birth defects
epidemiology. Teratology 45:187–193
Green DM, Fiorello A, ZevonMA,Hall B, SeigelsteinN (1997)
Birth defects and childhood cancer in offspring of survivors
of childhood cancer. Arch Pediatr Adolesc Med 151:
379–383
Hammond GD (1997) Principles of pediatric oncology. In:
Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Wei-
chselbaum RR (eds) Cancer medicine, 4th ed. Williams &
Wilkins, Baltimore, pp 2885–2890
Harrison BR (1996) Safe handling of cytotoxic drugs. In: Perry
MC (ed) The chemotherapy source book, 2d ed. Williams
& Wilkins, Baltimore, pp 905–942
Haskell CM (ed) (1980) Cancer treatment. WB Saunders,
Philadelphia
——— (ed) (1995) Cancer treatment, 4th ed. WB Saunders,
Philadelphia
Kenney LB, Nicholson HS, Brasseaux C, Mills JL, Robison
LL, Zeltzer LK, Meadows AT, et al (1996) Birth defects in
offspring of adult survivors of childhood acute lympho-
blastic leukemia: a Childrens Cancer Group/National Insti-
tutes of Health report. Cancer 78:169–176
Klein CE (1996) Gonadal complications and teratogenicity of
cancer therapy. In: Perry MC (ed) The chemotherapy source
book, 2d ed. Williams & Wilkins, Baltimore, pp 813–832
Meistrich ML, Wilson G, Brown BW, da Cunha MF, Lipshultz
LI (1992) Impact of cyclophosphamide on long-term re-
duction in sperm count in men treated with combination
chemotherapy for Ewing and soft tissue sarcomas. Cancer
70:2703–2712
Milunsky A, Graef JW, Gaynor MF (1968) Methotrexate-in-
duced congenital malformations. J Pediatr 72:790–795
Otake M, Schull WJ (1984) In utero exposure to A-bomb
radiation and mental retardation: a reassessment. Br J Ra-
diol 57:409–414
Perry MC (ed) (1996) The chemotherapy source book, 2d ed.
Williams & Wilkins, Baltimore
Sankaranarayanan K (1991) Ionizing radiation and genetic
risks. II. nature of radiation-induced mutations in experi-
mental mammalian in vivo systems. Mutat Res 258:51–73
——— (1994) International Commission for Protection
Against Environmental Mutagens and Carcinogens, work-
ing paper number 6: estimation of genetic risks of exposure
to chemical mutagens: relevance of data on spontaneous
mutations and of experience with ionizing radiation. Mutat
Res 304:139–148
Shelby MD (1994) Human germ cell mutagens. Environ Mol
Mutagen 23 Suppl 24:30–34.
Warkany J (1978) Aminopterin and methotrexate: folic acid
deficiency. Teratology 17:353–357
Watson AR, Rance CP, Bain J (1985) Long term effects of
cyclophosphamide on testicular function. Br Med J Clin Res
291:1457–1460
Witt KL, Bishop JB (1996) Mutagenicity of anticancer drugs
in mammalian germ cells. Mutat Res 355:209–234
